Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai's Everest Medicines Stages $451 Million Hong Kong IPO

publication date: Oct 9, 2020

Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop its portfolio of eight assets in-licensed for China development. The company's stock climbed 32% in its first trading session. Founded in 2017, Everest was incubated by CBC Group (formerly C-Bridge Capital) to be its China in-licensing company. The company's eight products address needs in oncology, immunology, cardio-renal and infectious diseases, several of which are in late-stage development or have filed for approval. More details....

Stock Symbol: (HK:1952)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.